Generated by AI
SCYNEXIS, Inc. is a clinical-stage biotechnology company focused on developing innovative medicines for severe rare diseases and difficult-to-treat infections. Its current lead program is SCY-770, a selective direct AMP-activated protein kinase activator being developed for autosomal dominant polycystic kidney disease, a progressive inherited disorder affecting kidney structure and function. The company also maintains expertise in antifungal drug development, including ibrexafungerp, an oral and intravenous triterpenoid antifungal marketed in the United States as BREXAFEMME for vulvovaginal candidiasis and reducing recurrent infections. This portfolio addresses significant unmet needs in infectious disease and rare kidney disorders, where treatment options can be limited or complicated by resistance, recurrence, or disease progression. SCYNEXIS, Inc. operates within the biopharmaceutical market, combining drug discovery, clinical development, regulatory activities, intellectual-property management, and commercialization partnerships to advance targeted therapies from research through patient access. Its work contributes to specialty pharmaceutical markets serving patients, healthcare providers, and systems managing complex medical conditions.
Website1 Evertrust Plaza
Jersey City, NJ, 07302-6548
United States
The latest articles about SCYX.
Summary of Oct 6's posts. Generated by AI.
Summary of Nov 20's posts. Generated by AI.
Summary of Oct 20's posts. Generated by AI.
Summary of Sep 28's posts. Generated by AI.
Investors talking about SCYX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.